TherapeuticsMD, Inc. (NYSE MKT:TXMD) (the "Company"), a women’s health care product company, announced today the pricing of a previously announced underwritten secondary public offering of 9,000,000 shares of its common stock, offered at a price of $7.10 per share. All shares are offered by the selling stockholders, including certain members of management of the Company and certain of their and the Company’s affiliates. The Company will not sell any shares or receive any proceeds from the offering. The offering is expected to close on or about March 26, 2014, subject to the satisfaction of customary closing conditions. In addition, certain of the selling stockholders have granted the underwriters a 30-day option to purchase up to an aggregate of 1,350,000 additional shares of common stock.
Jefferies LLC and Stifel are acting as joint book-running managers for the offering, and Cowen and Company, LLC and Mizuho Securities USA Inc. are acting as co-managers for the offering.
A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed by the Company with the Securities and Exchange Commission (“SEC”) and has been declared effective by the SEC. A preliminary prospectus supplement related to the offering has been filed with the SEC and a final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com; and from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, 36th Floor, San Francisco, CA 94104, by telephone at (415) 364-2720, or by e-mail at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.